Advertisement

Present Status of Anticoagulant Prophylaxis

  • J. Donald Easton

Abstract

Although anticoagulation is widely used for stroke prevention, it has not been well studied and is substantially unproven in the management of cerebral vascular diseases. Even after nearly 40 years of use, major controversy questions its value in preventing infarction in patients with transient ischemic attack (TIA), in arresting progressing stroke, and in preventing cerebral reinfarction. Although most clinicians believe anticoagulants are effective in some situations, they question how well they work, and whether the bleeding risks outweigh the benefit. Anticoagulation using heparin and warfarin and the justification for its current role in the treatment of cerebral vascular disease will be reviewed in this chapter.

Keywords

Atrial Fibrillation Transient Ischernic Attack Stroke Prevention Rheumatic Heart Disease Cerebral Venous Thrombosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In: Gilman AG, Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics, 6th ed. New York, NY: Macmillan Publishing Co.: 1980: pp 1347–1360.Google Scholar
  2. 2.
    Hirsh J. Anticoagulant and platelet antiaggregant agents. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis and Management. New York, NY: Churchill, Livingstone: 1986: pp 925–966.Google Scholar
  3. 3.
    Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet. 1977; 2:581–584.PubMedCrossRefGoogle Scholar
  4. 4.
    Schafer, AI. The hypercoagulable states. Ann Int Med. 1985;102:814–828.PubMedCrossRefGoogle Scholar
  5. 5.
    Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1:1242–1245.PubMedCrossRefGoogle Scholar
  6. 6.
    Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural myocardial infarction. N Engl J Med. 1989;320:352–357.PubMedCrossRefGoogle Scholar
  7. 7.
    Koch Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med. 1971;285: 487–498,CrossRefGoogle Scholar
  8. 7a.
    Koch Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. N Engl J Med. 1971;285: 547–558.PubMedCrossRefGoogle Scholar
  9. 8.
    Report of the Veterans Administration. Cooperative Study of Atherosclerosis, Neurology Section. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Neurology. 1961;11:132–138.CrossRefGoogle Scholar
  10. 9.
    Baker RN, Broward JA, Fang HC, et al. Anticoagulant therapy in cerebral infarction. Neurology. 1962;12:823–835.PubMedCrossRefGoogle Scholar
  11. 10.
    Pearce JMS, Gubbay SS, Walton JN. Long-term anticoagulant therapy in transient cerebral attacks. Lancet. 1965;1:6–9.PubMedCrossRefGoogle Scholar
  12. 11.
    Baker RN, Schwartz W, Rose AS. Transient ischemic attacks — a report of a study of anticoagulant treatment. Neurology. 1966;16:841–847.CrossRefGoogle Scholar
  13. 12.
    Easton JD, Hart RG, Sherman DG, et al. Diagnosis and management of ischemic stroke: I. Threatened stroke and its management. Current Probl Cardiol. 1983;8:1–76.Google Scholar
  14. 13.
    Olsson JE, Brechter C, Backlund H, et al. Anticoagulant vs. anti-platelet therapy as prophylaxis against cerebral infarction in transient ischemic attacks. Stroke. 1980;11:4–9.PubMedCrossRefGoogle Scholar
  15. 14.
    Buren A, Ygge J. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke. 1981;12:578–580.PubMedCrossRefGoogle Scholar
  16. 15.
    Byer JA, Easton JD. Therapy of ischemic cerebrovascular disease. Ann Int Med. 1980;93:742–756.PubMedCrossRefGoogle Scholar
  17. 16.
    Easton JD, Sherman DG. Management of cerebral embolism of cardiac origin. Stroke. 1980;11:433–442.PubMedCrossRefGoogle Scholar
  18. 17.
    Hart RG, Sherman DG, Miller VT, et al. Diagnosis and management of ischemic stroke: II- Selected controversies. Current Probl Cardiol. 1983;8:1–80.Google Scholar
  19. 18.
    Putnam SF, Adams HP Jr. Usefulness of heparin in initial management of patients with recent transient ischemic attacks. Arch Neurol. 1985;42:960–962.CrossRefGoogle Scholar
  20. 19.
    Jones HR, Millikan CH, Sandok BA. Temporal profile (clinical course) of acute vertebrobasilar system cerebral infarction. Stroke. 1980;11:173–177.PubMedCrossRefGoogle Scholar
  21. 20.
    Jones HR, Millikan CH. Temporal profile (clinical course) of acute carotid system cerebral infarction. Stroke. 1976;7:64–71.PubMedCrossRefGoogle Scholar
  22. 21.
    Duke RJ, Bloch RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized controlled trial. Ann Int Med. 1986;105:825–828.PubMedCrossRefGoogle Scholar
  23. 22.
    Whisnant JP. Discussion of progressing stroke: anticoagulant therapy. In: Millikan CH, Siekert RH, Whisnant JP, eds. Cerebral Vascular Diseases. Third Princeton Conference. New York, NY: Grune & Stratton: 1961: pp 182–183.Google Scholar
  24. 23.
    Marquardsen J. The natural history of acute cerebrovascular disease. A retrospective study of 769 patients. Acta Neurol Scand. 1969;45(suppl 38): 1–192.Google Scholar
  25. 24.
    Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke: design, organization and baseline results. Stroke. 1988;19:1203–1210.PubMedCrossRefGoogle Scholar
  26. 25.
    Sherman DG, Dyken ML, Fisher M, et al. Cerebral embolism. Chest. 1986; 89(suppl): 83S-98S.Google Scholar
  27. 26.
    Chesebro JH, Fuster V, Pumphrey CW, et al. Combined warfarin-platelet inhibitor antithrombotic therapy in prosthetic heart valve replacement. Circulation. 1981;64(suppl IV)76.Google Scholar
  28. 27.
    Beer DT, Ghitman B. Embolization from the atria in arteriosclerotic heart disease, JAMA. 1961;177: 287 – 291.PubMedCrossRefGoogle Scholar
  29. 28.
    Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973–977.PubMedCrossRefGoogle Scholar
  30. 29.
    Bharucha NE, Wolf PA, Kannel WB, et al. Epidemiological study of cerebral embolism: the Framingham Study. Ann Neurol. 1981;10:105.Google Scholar
  31. 30.
    Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke. 1983;14:664–667.PubMedCrossRefGoogle Scholar
  32. 31.
    Hart RG, Easton JD, Sherman DG. Duration of nonvalvular atrial fibrillation and stroke. Stroke. 1983; 14:827.PubMedGoogle Scholar
  33. 32.
    Petersen P, Boysen G, Godtfredsen J, et al. Placebocontrolled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175–179.PubMedCrossRefGoogle Scholar
  34. 33.
    Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med. 1990;322:863–868.Google Scholar
  35. 34.
    Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511.CrossRefGoogle Scholar
  36. 35.
    Bean WB. Infarction of the heart. III. Clinical course and morphological findings. Ann Int Med. 1938;12:71–94.CrossRefGoogle Scholar
  37. 36.
    Friedman MJ, Carlson K, Marcus FI, et al. Clinical correlations in patients with acute myocardial infarction and left ventricular thrombus detected by two-dimensional echocardiography. Am J Med. 1982;72:894–898.PubMedCrossRefGoogle Scholar
  38. 37.
    Asinger RW, Mikell FL, Elsperger J, et al. Incidence of left ventricular thrombosis after acute transmural myocardial infarction. N Engl J Med. 1981;305: 297–302.PubMedCrossRefGoogle Scholar
  39. 38.
    Meltzer RS, et al. Intracardiac thrombi and systemic embolisation. Ann Int Med. 1986;104:689–698.PubMedCrossRefGoogle Scholar
  40. 39.
    Resnekov L, et al. Antithrombotic agents in coronary artery disease. Chest. 1986;89:54S.Google Scholar
  41. 40.
    Demakis JG, Proskey A, Rahimatoola SH, et al. The natural course of alcoholic cardiomyopathy. Ann Int Med. 1974;80:293–297.PubMedCrossRefGoogle Scholar
  42. 41.
    McDonald CD, Burch GE, Walsh JJ. Prolonged bedrest in the treatment of idiopathic cardiomyopathy. Am J Med. 1972;52:41–50.PubMedCrossRefGoogle Scholar
  43. 42.
    Vost A, Wolochow DA, Howell DA. Incidence of infarcts of the brain in heart disease. J Pathol Bacteriol. 1964;88:463–470.PubMedCrossRefGoogle Scholar
  44. 43.
    Hart RG, Easton JD. Dissections and trauma of cervico-cerebral arteries. In: Barnett HJM, Mohr JP, Stein BM, et al., eds. Stroke: Pathophysiology, Diagnosis and Management. New York, NY: Churchill, Livingstone: 1986: pp 775–788.Google Scholar
  45. 44.
    Mokri B, Sundt TM Jr, Houser OW, et al. Spontaneous dissection of the cervical internal carotid artery. Ann Neurol. 1986;19:126–138.PubMedCrossRefGoogle Scholar
  46. 45.
    Biller J, Hingtgen WL, Adams HP Jr, et al. Cervicocephalic arterial dissections. A ten year experience. Arch Neurol. 1986;43:1234–1238.PubMedCrossRefGoogle Scholar
  47. 46.
    Bogousslaysky J, Despland P-A, Regli F. Spontaneous carotid dissection with acute stroke. Arch Neurol. 1987;44:137–140.CrossRefGoogle Scholar
  48. 47.
    Chapleau CE, Robertson JT. Spontaneous cervical carotid artery dissection: outpatient treatment with continuous heparin infusion using a totally implantable infusion device. Neurosurg. 1981;8:83.CrossRefGoogle Scholar
  49. 48.
    Fisher CM, Ojemann RG, Robertson GH. Spontaneous dissection of cervicocerebral arteries. Can J Neurol Sci. 1978;5:9.PubMedGoogle Scholar
  50. 49.
    McNeill DH Jr, Dreisback J, Marsden RJ. Spontaneous dissection of the internal carotid artery: its consecutive management with heparin sodium. Arch Neurol. 1980;37:54.PubMedCrossRefGoogle Scholar
  51. 50.
    Sherman DG, Hart RG, Easton JD. Abrupt change in head position and cerebral infarction. Stroke. 1981; 12:2.PubMedCrossRefGoogle Scholar
  52. 51.
    Bousser M-G, Chiras J, Bories J, et al. Cerebral venous thrombosis-a review of 38 cases. Stroke. 1985; 16:199–213.PubMedCrossRefGoogle Scholar
  53. 52.
    Fairburn B. Intracranial venous thrombosis complicating oral contraception: treatment by anticoagulant drugs. Br Med J. 1973;2:647.PubMedCrossRefGoogle Scholar
  54. 53.
    Kalbag RM, Woolf AL. Cerebral Venous Thrombosis. London: University Press; 1967.Google Scholar
  55. 54.
    Hart RG, Coull BM. Hypercoagulability following coumadin withdrawal. Am Heart J. 1983;106:169–170.PubMedCrossRefGoogle Scholar
  56. 55.
    Hart RG, Coull BM, Miller VT. Rebound hypercoagulability. Stroke. 1982;13:527.CrossRefGoogle Scholar
  57. 56.
    Slivka AP, Levy DE. Risk associated with heparin withdrawal in ischemic cerebrovascular disease. Stroke. 1987;18:298. Abstract.CrossRefGoogle Scholar
  58. 57.
    Tinker JH, Tarnahan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. JAMA. 1978;239:738–739.PubMedCrossRefGoogle Scholar
  59. 58.
    Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. Am Heart J. 1978;96:163–165.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • J. Donald Easton

There are no affiliations available

Personalised recommendations